[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tang Xiaodong\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100617115","phase-4-the-effect-of-preoperative-intravenous-ferric-derisomaltose-and-epo-and-tranexamic-acid-in-patients-with-preoperative-anemia-or-iron-deficiency-in-bone-tumor-100617115",false,"NCT07314424","The Effect of Preoperative Intravenous Ferric Derisomaltose and EPO and Tranexamic Acid in Patients With Preoperative Anemia or Iron Deficiency in Bone Tumor","The Effect of Preoperative Intravenous Ferric Derisomaltose and EPO and Tranexamic Acid Versus Usual Treatment in Patients With Preoperative Anemia or Iron Deficiency in Bone Tumor: a Single-center, Prospective, Open-label, RCT Study","Inclusion criteria:\n\n* Patients aged 18 and above with primary malignant bone tumors and bone metastases who plan to undergo open surgery for the sacrum, pelvis, and spine.\n* 5 ± 2 days before surgery, hemoglobin\\\u003C130g\u002FL, or iron deficiency (TSAT\\\u003C20%)\n* Patients are able to understand the research content and sign informed consent forms\n\nExclusion criteria:\n\nMeet any of the following criteria;\n\n* Ferritin\\>800 ng\u002Fml or hemoglobin\\\u003C70 g\u002FL\n* Expected survival period less than six months\n* Women who are pregnant, breastfeeding, or planning to conceive\n* Known to have allergic reactions to other iron agents\n* Severe bone marrow suppression event (4th degree bone marrow suppression) occurred 4 weeks before enrollment\n* Decompensated stage of liver disease\n* Patients with combined acute phase infections\n* Chronic kidney disease stage 3-5\n* Patients who received oral iron, intravenous iron, EPO, or blood transfusion treatment within one month prior to the start of the study.\n* Researchers believe that other conditions that are not suitable for participation in this study, such as deafness, Parkinson's disease, communication disorders, etc\n* Participated in other clinical trials within the three months prior to participating in this study","ALL","18 Years","65 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The pelvis and spine are common sites of primary and secondary bone tumors, and most patients require surgical treatment. However, due to bleeding, high tumor burden, and other reasons, iron deficiency anemia (IDA) is common in these patients. At present, allogeneic blood resources are scarce in China and even globally, and cancer patients cannot undergo autologous blood transfusion. In addition, there is a large amount of bleeding during pelvic and spinal open surgery, which collectively leads to a high incidence of perioperative anemia in patients with pelvic and spinal tumors, and even the loss of surgical opportunities. Therefore, perioperative blood management for bone tumor surgery is extremely important. The combination of intravenous iron and EPO has been proven to rapidly improve the hemoglobin levels of perioperative surgical patients in previous studies, but there is currently no research related to bone tumors. This study uses a single center, prospective, open label, randomized controlled clinical trial to explore the effects of preoperative application of intravenous isomaltose iron combined with erythropoietin and tranexamic acid compared to conventional treatment in patients with preoperative anemia or iron deficiency in bone tumor surgery, hoping to establish a standard paradigm for perioperative blood management in bone tumor patients.",[27],"Anemia",[29,30,31,32],"anemia","bone tumor","perioperative","Blood management","NOT_YET_RECRUITING","2025-12-17",{"date":36,"type":37},"2026-01-02","ACTUAL",{"date":39,"type":21},"2026-01-01",{"date":41,"type":21},"2027-10-01",{"name":43,"class":44},"Tang Xiaodong","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100600039","phase-2-a-randomized-controlled-study-comparing-the-safety-and-efficacy-of-irinotecan-hydrochloride-liposome-injection-combined-with-temozolomide-and-vincristine-naliri-vt-versus-irinotecan-combined-with-temozolomide-and-vincristine-vit-in-patients-with-advanced-ewings-sarcoma-100600039","NCT07092306","A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma","Inclusion Criteria:\n\n* 1\\. The subject or their legal representative must sign the written informed consent before enrollment.\n\n  2\\. Age ≥ 8 years and ≤ 40 years, both male and female are eligible. 3. Pathologically confirmed Ewing's sarcoma, and detailed pathological reports must be provided. Pathology must be confirmed by fluorescence in situ hybridization (FISH) or next-generation sequencing (NGS) to show the presence of Ewing's sarcoma-specific FET family (including EWSR1 or FUS) gene breaks. This study does not impose special restrictions on fusion partner genes, but clear FET-non ETS fusions (such as EWSR1-WT1, EWSR1-NFATC2, EWSR1-PATZ1, etc.) do not meet the enrollment criteria.\n\n  4\\. At least one measurable target lesion as judged by RECIST 1.1 criteria. 5. Failure of first-line standard treatment. First-line standard treatment includes the following drugs: doxorubicin, cyclophosphamide and\u002For ifosfamide. Treatment failure is defined as disease progression during adjuvant chemotherapy or within 6 months after chemotherapy. For disease progression more than 6 months after chemotherapy, the consent of the subject or their legal representative is required.\n\n  6\\. ECOG score: 0-1. 7. Expected survival ≥ 3 months. 8. Recovery from previous treatment: According to NCI-CTCAE 5.0, all side effects (except alopecia) must have subsided to grade 1 or below.\n\n  9\\. Normal major organ function, meeting the following criteria:\n\n  1\\) Blood routine examination must meet the following criteria (no blood transfusion, no use of hematopoietic factors, and no drug correction within 14 days):\n  1. ANC ≥ 1.5×109\u002FL;\n  2. HB ≥ 90 g\u002FL;\n  3. PLT ≥ 100×109\u002FL; 2) Biochemical examination must meet the following criteria:\n\n  \u003C!-- -->\n\n  1. TBIL ≤ 1.5 ULN;\n  2. ALT, AST ≤ 2.5 ULN (if liver function abnormalities are due to liver metastasis, then ≤ 5 ULN);\n  3. Serum creatinine sCr ≤ 1.5 ULN, endogenous creatinine clearance rate ≥ 50 ml\u002Fmin (Cockcroft-Gault formula); 3) Coagulation function must meet the following criteria: INR ≤ 1.5 and APTT ≤ 1.5 ULN.\n\n     10\\. Women of childbearing age must have taken reliable contraceptive measures or undergone a pregnancy test (serum or urine) within one week before enrollment, with a negative result, and be willing to use appropriate contraceptive methods during the trial and for 8 weeks after the last administration of the investigational drug. For men, they must agree to use appropriate contraceptive methods during the trial and for 8 weeks after the last administration of the investigational drug or have undergone surgical sterilization.\n\n     Exclusion Criteria:\n* 1\\. Known hypersensitivity, anaphylaxis or intolerance to irinotecan liposome, temozolomide and vincristine or their excipients; 2. Within 2 weeks after the last systemic cytotoxic drug treatment, radiotherapy, targeted therapy or any anti-tumor drug treatment except immunotherapy; 3. Patients who have received irinotecan treatment before; 4. Other malignant tumors within the past 5 years; 5. Known symptomatic central nervous system metastases; 6. Known symptomatic brain metastases, spinal cord compression, carcinomatous meningitis, or unstable brain or leptomeningeal disease found on CT or MRI at screening; 7. Symptomatic serous cavity effusion (including pleural effusion, ascites, pericardial effusion) requiring surgical intervention; 8. Uncontrolled concomitant diseases, including but not limited to: poorly controlled hypertension, heart failure, diabetes, persistent active infection, poorly controlled active peptic ulcer, or mental disorders or social conditions that may affect the subject's compliance with the study; 9. Abnormal coagulation function (INR \\> 1.5 or prothrombin time (PT) \\> ULN + 4s or APTT \\> 1.5 ULN), with bleeding tendency or receiving thrombolytic or anticoagulant therapy; 10. Treatment with anticoagulants or vitamin K antagonists such as warfarin, heparin or similar drugs; Note: Under the condition of INR ≤ 1.5, low-dose heparin (adult daily dose of 6,000 - 12,000 U), low-dose aspirin (daily dose ≤ 100 mg), or rivaroxaban (daily dose ≤ 10 mg) for preventive purposes is allowed; 12. History of drug abuse of psychotropic drugs and unable to quit or with mental disorders; 13. Known hereditary or acquired bleeding and thrombotic tendencies (such as hemophilia, coagulation disorders, thrombocytopenia, hypersplenism, etc.); 14. Open wounds, fractures, or poorly healing wounds; 15. Major surgery within 2 weeks; 16. Confirmed inflammatory bowel disease, intestinal obstruction or chronic diarrhea; 17. Cavity organ fistula or perforation within 6 months; 18. Active hepatitis B or C virus infection or active infection requiring antimicrobial treatment (such as the use of antibacterial drugs, antiviral drugs, antifungal drugs); 19. Participation in other interventional anti-tumor clinical trials within 4 weeks; 20. Patients who have used strong CYP3A4 inducers or strong CYP3A4 inhibitors or strong UGT1A1 inhibitors within 3 weeks before the first dose; 21. Lactation; 22. Any condition that the investigator deems may harm the patient or prevent the patient from meeting or fulfilling the study requirements.","8 Years","40 Years",{"count":54,"type":21},74,[56],"PHASE2","This study is a randomized, controlled, multicenter, prospective clinical trial with a planned enrollment of 74 patients, who will be randomly assigned in a 2:1 ratio. After enrollment, patients will receive either irinotecan liposomal injection combined with temozolomide and vincristine or irinotecan injection combined with temozolomide and vincristine. The aim is to evaluate the efficacy, safety, and impact on quality of life of the irinotecan liposomal combination regimen compared to the irinotecan injection combined with temozolomide and vincristine in the treatment of advanced Ewing's sarcoma.",[59],"Ewing's Sarcoma",[61,62,63,64,59],"Irinotecan Hydrochloride Liposome Injection","NALIRI-VT","Temozolomide","Vincristine","2025-07-22",{"date":67,"type":37},"2025-07-29",{"date":69,"type":21},"2025-08-10",{"date":71,"type":21},"2027-05-01",{"name":43,"class":44},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100565878","phase-1-efficacy-of-icg-based-nir-imaging-in-intralesional-curettage-of-giant-cell-tumors-of-bone-in-limbs-a-prospective-single-center-single-arm-open-study-100565878","NCT06647901","Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study","Inclusion Criteria:\n\n1. . Aged 18-65.\n2. Biopsy confirmed giant cell tumor of bone.\n3. The lesions located in the limbs.\n4. This operation is the initial treatment.\n5. Denosumab and diphosphonates are not used before surgery.\n6. Planned operation is intralesional curettage and filling bone defects with bone cement.\n7. Preoperative bone scan and thin layer (layer thickness ≤3.5mm) chest CT plain scan confirmed that the lesion is a single occurrence without metastasis.\n8. Subjects fully understand the benefits and risks of this experiment and are still willing to participate and sign the informed consent.\n\nExclusion Criteria:\n\n1. . Known allergy to iodine contrast, indocyanine green or bone cement.\n2. . Severe hepatic and renal insufficiency.\n3. . During pregnancy or lactation.\n4. . Have other malignant tumors and are receiving related medical treatment.",{"count":80,"type":21},45,[82,56],"PHASE1","ICG fluorescence imaging will be applied during the intralesional curettage of giant cell tumor of bone in the limbs. This study aims to preliminarily explore whether ICG fluorescent-guided curettage could find small residual tumors and reduce the recurrence rate of tumor.",[85],"Giant Cell Tumor of Bone",[87,88,89],"ICG","Giant cell tumor of bone","curettage","RECRUITING","2024-10-16",{"date":93,"type":37},"2024-10-18",{"date":95,"type":37},"2024-08-23",{"date":97,"type":21},"2028-08-31",{"name":43,"class":44},1,""]